Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells

Immunology and Cell Biology

Volumn 89, Issue 7, 2011, Pages 792-802

  Leung, Lawrence W ^a   Park, Man Seong ^a,b   Martinez, Osvaldo ^a   Valmas, Charalampos ^a   López, Carolina B ^a,c   Basler, Christopher F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Hallym University   (South Korea)

^c UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

Author keywords

dendritic cell; ebolavirus; interferon; IRF7

Indexed keywords

INTERFERON REGULATORY FACTOR 7; PROTEIN VP35; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CYTOKINE PRODUCTION; EBOLA VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; MACROPHAGE; NEWCASTLE DISEASE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PLASMACYTOID DENDRITIC CELL; RNA VIRUS INFECTION;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; DEAD-BOX RNA HELICASES; DENDRITIC CELLS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNITY, INNATE; INTERFERON REGULATORY FACTOR-7; INTERFERONS; MACROPHAGES; MICE; NEWCASTLE DISEASE VIRUS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA; VERO CELLS; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EBOLA VIRUS; NEWCASTLE DISEASE VIRUS; RNA VIRUSES;

EID: 80053929813     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.169     Document Type: Article

References (57)

1. Bray M, Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 2005; 37: 1560-1566. (Pubitemid 40719635)
2. Geisbert TW, Hensley LE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 2004; 6: 1-24.
3. Sanchez A, Geisbert TW, Feldmann H. Marburg and ebola viruses. In: DM Knipe, PM Howley (eds). Fields Virology, 5 edn. Vol. 1, Lippincott Williams and Wilkins: Philadelphia, 2007, pp 1409-1448.
4. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163: 2347-2370. (Pubitemid 37466478)
5. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, Negley D et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003; 188: 1630-1638. (Pubitemid 38010672)
6. Hartman AL, Dover JE, Towner JS, Nichol ST. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J Virol 2006; 80: 6430-6440. (Pubitemid 43927446)
7. Hartman AL, Ling L, Nichol ST, Hibberd ML. Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol 2008; 82: 5348-5358. (Pubitemid 351705242)
8. Prins KC, Delpeut S, Leung DW, Reynard O, Volchkova VA, Reid SP et al. Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J Virol 2010; 84: 3004-3015.
9. Basler CF, Amarasinghe GK. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res 2009; 29: 511-520.
10. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, Bray M et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 2003; 77: 7945-7956. (Pubitemid 36792791)
11. Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk HD et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 2000; 97: 12289-12294.
12. Cardenas WB, Loo YM, Gale Jr M, Hartman AL, Kimberlin CR, Martinez-Sobrido L et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 2006; 80: 5168-5178.
13. Prins KC, Cardenas WB, Basler CF. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol 2009; 83: 3069-3077.
14. Kimberlin CR, Bornholdt ZA, Li S, Woods Jr VL, MacRae IJ, Saphire EO. Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc Natl Acad Sci USA 2010; 107: 314-319.
15. Leung DW, Prins KC, Borek DM, Farahbakhsh M, Tufariello JM, Ramanan P et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol 2010; 17: 165-172.
16. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005; 23: 19-28. (Pubitemid 41019654)
17. Yoneyama M, Fujita T. Function of RIG-I-like receptors in antiviral innate immunity. J Biol Chem 2007; 282: 15315-15318. (Pubitemid 47093255)
18. Spiropoulou CF, Ranjan P, Pearce MB, Sealy TK, Albarino CG, Gangappa S et al. RIG-I activation inhibits ebolavirus replication. Virology 2009; 392: 11-15.
19. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 2004; 78: 10370-10377. (Pubitemid 39258362)
20. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 1999; 179(Suppl 1): S188-S191. (Pubitemid 29091401)
21. Rubins KH, Hensley LE, Wahl-Jensen V, Daddario DiCaprio KM, Young HA, Reed DS et al. The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol 2007; 8: R174.
22. Gupta M, Mahanty S, Ahmed R, Rollin PE. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology 2001; 284: 20-25. (Pubitemid 32476692)
23. Borderia AV, Hartmann BM, Fernandez-Sesma A, Moran TM, Sealfon SC. Antiviral-activated dendritic cells: a paracrine-induced response state. J Immunol 2008; 181: 6872-6881.
24. Escribese MM, Kraus T, Rhee E, Fernandez-Sesma A, Lopez CB, Moran TM. Estrogen inhibits dendritic cell maturation to RNA viruses. Blood 2008; 112: 4574-4584.
25. Fernandez-Sesma A, Marukian S, Ebersole BJ, Kaminski D, Park MS, Yuen T et al. Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol 2006; 80: 6295-6304. (Pubitemid 43927432)
26. Gabriele L, Fragale A, Borghi P, Sestili P, Stellacci E, Venditti M et al. IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. J Leukoc Biol 2006; 80: 1500-1511. (Pubitemid 44904989)
27. Kumagai Y, Kumar H, Koyama S, Kawai T, Takeuchi O, Akira S. Cutting edge: TLR-dependent viral recognition along with type I IFN positive feedback signaling masks the requirement of viral replication for IFN-{alpha} production in plasmacytoid dendritic cells. J Immunol 2009; 182: 3960-3964.
28. Matsui K, Kumagai Y, Kato H, Sato S, Kawagoe T, Uematsu S et al. Cutting edge: role of TANK-binding kinase 1 and inducible IkappaB kinase in IFN responses against viruses in innate immune cells. J Immunol 2006; 177: 5785-5789. (Pubitemid 44628791)
29. Habjan M, Andersson I, Klingstrom J, Schumann M, Martin A, Zimmermann P et al. Processing of genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction. PLoS One 2008; 3: e2032.
30. Park MS, Garcia-Sastre A, Cros JF, Basler CF, Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J Virol 2003; 77: 9522-9532. (Pubitemid 37011047)
31. Vigil A, Martinez O, Chua MA, Garcia-Sastre A. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther 2008; 16: 1883-1890.
32. Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 2007; 67: 8285-8292. (Pubitemid 47395166)
33. Bjorndal AS, Szekely L, Elgh F. Ebola virus infection inversely correlates with the overall expression levels of promyelocytic leukaemia (PML) protein in cultured cells. BMC Microbiol 2003; 3: 6.
34. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 2006; 80: 5156-5167.
35. Emeny JM, Morgan MJ. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol 1979; 43: 247-252. (Pubitemid 9181666)
36. Sumpter Jr R, Loo YM, Foy E, Li K, Yoneyama M, Fujita T et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005; 79: 2689-2699. (Pubitemid 40270547)
37. Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N et al. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol 2003; 77: 1501-1511. (Pubitemid 36055570)
38. Chang TH, Kubota T, Matsuoka M, Jones S, Bradfute SB, Bray M et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog 2009; 5: e1000493.
39. Jin H, Yan Z, Prabhakar BS, Feng Z, Ma Y, Verpooten D et al. The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. J Gen Virol 2010; 91(Pt 2): 352-361.
40. Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 2002; 80: 169-179. (Pubitemid 34136004)
41. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434: 772-777. (Pubitemid 44739521)
42. Levy DE, Marie I, Smith E, Prakash A. Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J Interferon Cytokine Res 2002; 22: 87-93. (Pubitemid 34161286)
43. Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J 1998; 17: 6660-6669. (Pubitemid 28521799)
44. Tailor P, Tamura T, Kong HJ, Kubota T, Kubota M, Borghi P et al. The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. Immunity 2007; 27: 228-239. (Pubitemid 47284921)
45. Joo CH, Shin YC, Gack M, Wu L, Levy D, Jung JU. Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3. J Virol 2007; 81: 8282-8292. (Pubitemid 47101513)
46. Wang F, Gao X, Barrett JW, Shao Q, Bartee E, Mohamed MR et al. RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog 2008; 4: e1000099.
47. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009; 22: 240-273.
48. Nakhaei P, Genin P, Civas A, Hiscott J. RIG-I-like receptors: sensing and responding to RNA virus infection. Semin Immunol 2009; 21: 215-222.
49. Pichlmair A, Reis e Sousa C. Innate recognition of viruses. Immunity 2007; 27: 370-383. (Pubitemid 47418682)
50. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006; 314: 997-1001. (Pubitemid 44749946)
51. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009; 227: 75-86.
52. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730-737. (Pubitemid 39023305)
53. Bosio CM, Moore BD, Warfield KL, Ruthel G, Mohamadzadeh M, Aman MJ et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology 2004; 326: 280-287. (Pubitemid 39078259)
54. Burke CW, Gardner CL, Steffan JJ, Ryman KD, Klimstra WB. Characteristics of alpha/ beta interferon induction after infection of murine fibroblasts with wild-type and mutant alphaviruses. Virology 2009; 395: 121-132.
55. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002; 128: 163-168. (Pubitemid 34451194)
56. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000; 355: 2210-2215. (Pubitemid 30394329)
57. Martinez O, Johnson J, Manicassamy B, Rong L, Olinger GG, Hensley LE et al. Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol 2010; 12: 148-157.